Literature DB >> 3762596

Low-molecular-weight heparin: is small beautiful?

E W Salzman.   

Abstract

Mesh：

Substances：

Year:  1986        PMID： 3762596     DOI： 10.1056/NEJM198610093151509

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Major orthopaedic surgery on the leg and thromboembolism.

Authors:  J Parker-Williams; R Vickers
Journal:  BMJ       Date:  1991-09-07

2.  Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.

Authors:  Beng H Chong; Tim A Brighton; Ross I Baker; Peter Thurlow; Choon H Lee
Journal:  J Thromb Thrombolysis       Date:  2005-06       Impact factor: 2.300

Review 3.  The pathogenesis and prevention of thromboembolic complications in patients undergoing total hip replacement.

Authors:  D K Potyk; H J Tabbarah
Journal:  J Gen Intern Med       Date:  1993-04       Impact factor: 5.128

Review 4.  Antiplatelet medications and evolving antithrombotic medication.

Authors:  Jonathan Ryan; Ferdia Bolster; Ian Crosbie; Eoin Kavanagh
Journal:  Skeletal Radiol       Date:  2013-01-19       Impact factor: 2.199

5.  Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.

Authors:  P F Leyvraz; F Bachmann; J Hoek; H R Büller; M Postel; M Samama; M D Vandenbroek
Journal:  BMJ       Date:  1991-09-07

Review 6.  Nadroparin calcium. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders.

Authors:  L B Barradell; M M Buckley
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

7.  Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice.

Authors:  S Frizelle; J Schwarz; S A Huber; K Leslie
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

Review 8.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

9.  A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting.

Authors:  Sonja Zindel; Stephanie Stock; Dirk Müller; Björn Stollenwerk
Journal:  BMC Health Serv Res       Date:  2012-07-09       Impact factor: 2.655
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.